Primary Treatment: Rifaximin SSD · Has Placebo Group · Phase 3
Rifaximin SSD-40mg IR
Experimental Group · 1 Intervention: Rifaximin SSD · Intervention Types: Drug
PlaceboComparator Group · 1 Intervention: Placebo · Intervention Types: Drug
Drug Approval Stage
How many patients have taken this drug
Screening: ~3 weeks
Reporting: 72 weeks
Who is running the clinical trial?
Bausch Health Americas, Inc.Lead Sponsor
260 Previous Clinical Trials
81,582 Total Patients Enrolled
John LaheyStudy DirectorBausch Health
5 Previous Clinical Trials
1,012 Total Patients Enrolled
Age 18+ · All Participants · 5 Total Inclusion Criteria
Mark “yes” if the following statements are true for you:
You have a diagnosis of advanced liver cirrhosis with medically controlled ascites (>30 days) not requiring therapeutic paracentesis (prophylactic variceal banding allowed if no history of previous variceal bleeding).
You have a mini-mental state examination score of 24 or greater.
Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.